Bayer to acquire KaNDy Therapeutics in $875M women’s health play
KaNDy's lead product candidate, NT-814, is a non-hormonal treatment for symptoms of menopause. The drug completed Phase IIb testing and is slated to start Phase III testing next year.
UK-based KaNDy Therapeutics raises $32.5 million Series C round, led by US firm
Longitude Capital leads round worth £25 million, which KaNDy will use to advance its non-hormonal menopause drug into Phase IIb clinical trial this year.
presented by
6 Aesthetic Certification Programs That Include Both Theory and Practical Training
Explore top-tier aesthetic certification programs that blend theory with hands-on training — perfect for health care pros ready to elevate their practice